Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy

Br J Haematol. 2019 Oct;187(2):e35-e38. doi: 10.1111/bjh.16155. Epub 2019 Aug 13.

Hamza Hashmi^{1

2}, Christina Bachmeier¹, Julio C Chavez^{3

4}, Jinming Song^{4

5}, Mohammad Hussaini^{4

5}, Gabriel Krivenko¹, Taiga Nishihori^{1

4}, Hiroshi Kotani⁶, Marco L Davila^{1

4}, Frederick L Locke^{1

4}, Michael D Jain^{1

4}

¹ Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
² Division of Hematology Oncology, University of Louisville, Louisville, KY, USA.
³ Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
⁴ Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
⁵ Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.
⁶ Division of Clinical Science, Moffitt Cancer Center, Tampa, FL, USA.

No abstract available

Keywords: chimeric antigen receptor T cell therapy; cytokine release syndrome; haemophagocytic lymphohistiocytosis.

Publication types